Tchaikapharma High Quality Medicines Inc.
Tchaikapharma High Quality Medicines Inc. is devoted to providing individuals and families with a wide range of affordable contemporary high-quality pharmaceuticals fighting socially significant diseases. The company focuses on the development and manufacturing of high-quality medicines, including generics and in-licensed medicines, with a proven cost-effectiveness ratio. It has a history of innovation, quality manufacturing, and expanding product portfolio, and is recognized as one of the most profitable and influential companies in Bulgaria. Tchaikapharma operates two manufacturing sites, has a significant market capitalization, and is committed to improving access to quality therapies and high standards of safety and efficacy.
Industries
Nr. of Employees
medium (51-250)
Tchaikapharma High Quality Medicines Inc.
Bulgaria, Emilia-Romagna, Italy, Europe
Products
Generic oral solid-dose medicines
Manufacture and marketing of generic coated and uncoated tablets and hard capsules across multiple therapeutic areas.
Sterile parenteral vials (dry vials) and labeled ampoules
Production and labeling of dry sterile vials for parenteral use and sterile ampoules.
Packaging and secondary packaging services
Primary and secondary packaging solutions including blistering, tamper-evident packaging, serialization-ready secondary packs and labeling.
Generic oral solid-dose medicines
Manufacture and marketing of generic coated and uncoated tablets and hard capsules across multiple therapeutic areas.
Sterile parenteral vials (dry vials) and labeled ampoules
Production and labeling of dry sterile vials for parenteral use and sterile ampoules.
Packaging and secondary packaging services
Primary and secondary packaging solutions including blistering, tamper-evident packaging, serialization-ready secondary packs and labeling.
Services
Contract manufacture of solid oral dosage forms and in‑licensed products under GMP for third-party partners.
Support for marketing authorization procedures including decentralised procedures where acting as Reference Member State.
Chemical and microbiological testing of raw materials, in-process samples and finished products supported by LIMS.
Implementation of serialization and tamper-evident packaging lines and related IT infrastructure to comply with EU requirements.
Pharmacovigilance processes and reporting channels for healthcare professionals and patients, including structured reporting forms.
Support for bioequivalence studies and clinical research through an on-site bioequivalence laboratory and clinical research department.
Contract manufacture of solid oral dosage forms and in‑licensed products under GMP for third-party partners.
Support for marketing authorization procedures including decentralised procedures where acting as Reference Member State.
Chemical and microbiological testing of raw materials, in-process samples and finished products supported by LIMS.
Implementation of serialization and tamper-evident packaging lines and related IT infrastructure to comply with EU requirements.
Pharmacovigilance processes and reporting channels for healthcare professionals and patients, including structured reporting forms.
Support for bioequivalence studies and clinical research through an on-site bioequivalence laboratory and clinical research department.
Expertise Areas
- GMP pharmaceutical manufacturing
- Solid dose formulation and production
- Sterile vial and parenteral handling
- Packaging automation and serialization
Key Technologies
- Granulation
- Dry-mixing
- Tableting
- Tablet coating
News & Updates
Therapeutic solutions ensure good control of cardiovascular diseases and increase patients’ quality of life. The company’s product 'Zornichka' marked a significant increase in sales.
Participation in the conference held in Sofia, presenting new products for treatment of socially significant diseases.
The company received marketing authorization for Telmira 60 mg and 90 mg tablets containing ticagrelor.
Ferbessa 4 mg/5 mg and 8 mg/5 mg tablets, a combination of perindopril and amlodipine, received marketing authorization.
The company provides alternatives for medicines missing due to supply chain issues, especially post-COVID-19 pandemic.
In February 2021, Tchaikapharma’s market capitalization reached over 1.13 billion leva, making it a leading pharmaceutical company in Bulgaria.
Therapeutic solutions ensure good control of cardiovascular diseases and increase patients’ quality of life. The company’s product 'Zornichka' marked a significant increase in sales.
Participation in the conference held in Sofia, presenting new products for treatment of socially significant diseases.
The company received marketing authorization for Telmira 60 mg and 90 mg tablets containing ticagrelor.
Ferbessa 4 mg/5 mg and 8 mg/5 mg tablets, a combination of perindopril and amlodipine, received marketing authorization.
The company provides alternatives for medicines missing due to supply chain issues, especially post-COVID-19 pandemic.
In February 2021, Tchaikapharma’s market capitalization reached over 1.13 billion leva, making it a leading pharmaceutical company in Bulgaria.